Michael Mayle
Family Medicine · Coloma, MINPI 1851403307
Payments from drug & device makers
Across 116 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$954
- Amgen$399
- AstraZeneca$179
- Lilly USA, LLC$88
- Biohaven Pharmaceuticals, Inc.$84
- Johnson & Johnson$78
- plus $421 from 14 others
What the payments were for
- Food & beverage$2,16898%
- Education$342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $954 |
| Amgen | 7 | $399 |
| AstraZeneca | 4 | $179 |
| Lilly USA, LLC | 5 | $88 |
| Biohaven Pharmaceuticals, Inc. | 2 | $84 |
| Johnson & Johnson | 2 | $78 |
| AbbVie(2 entities) | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Novartis | 3 | $54 |
| GSK | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Boehringer Ingelheim | 2 | $26 |
| Merck | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,202 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $174,333 |
| MounjaroTirzepatide | 103 | $118,012 |
| FarxigaDapagliflozin Propanediol | 112 | $115,946 |
| EliquisApixaban | 133 | $104,266 |
| JardianceEmpagliflozin | 85 | $104,037 |
| TrulicityDulaglutide | 78 | $101,117 |
| OxycontinOxycodone Hcl | 24 | $73,208 |
| MyrbetriqMirabegron | 55 | $58,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $46,325 |
| XareltoRivaroxaban | 43 | $45,880 |
| InvokanaCanagliflozin | 27 | $38,286 |
| VraylarCariprazine Hcl | 21 | $32,200 |
| JanuviaSitagliptin Phosphate | 21 | $26,695 |
| RybelsusSemaglutide | 18 | $22,465 |
| Nurtec OdtRimegepant Sulfate | 20 | $20,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $88 | $219,130181 claims |
| Novo NordiskOzempic, Rybelsus | $954 | $196,798165 claims |
| PfizerEliquis, Nurtec Odt | $11 | $124,361153 claims |
| AstraZenecaFarxiga | $179 | $115,946112 claims |
| Boehringer IngelheimJardiance | $26 | $104,03785 claims |
| Johnson & JohnsonXarelto, Invokana | $78 | $84,16570 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $45 | $72,74498 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $58,27155 claims |
| AbbVieVraylar, Linzess | $67 | $44,85543 claims |
| MerckJanuvia | $24 | $26,69521 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $59 | $18,17924 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $18 | $16,22311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Coloma
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.